Medication Therapy Management, Pharmacogenomics
Conditions
Keywords
Medication Therapy Management, Pharmacogenomics
Brief summary
The purpose of this study is to identify challenges and successes associated with implementing an enhanced medication therapy management service in primary care practice.
Detailed description
The specific aim of this study is to implement a Medication Therapy Management (MTM) service in primary care that is enhanced by the incorporation of pharmacogenomics (PGx) and medication risk mitigation (MRM) factor technology and is standardized by a systematic approach to evidence- and personalized-based medicine. The primary objective is to implement the systematic approach to delivering an enhanced MTM service in a primary care setting. Secondary objectives include: determine how successful the communication between prescriber and pharmacist is within implementing the service, determine how PGx testing can be incorporated into primary care prescribers' daily work flow, determine if patients are receptive to PGx testing, determine how satisfied prescribers are with an enhanced MTM clinical service and their confidence to conduct on their own, and determine if enhanced MTM optimizes or changes drug therapy for patients.
Interventions
OTHERMedication therapy management
Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
Sponsors
Tabula Rasa HealthCare
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Receiving primary health care from Elmwood Family Physicians; and * Medicare beneficiary; and * Currently prescribed at least 7 medications, or prescriber feels patient would benefit from enhanced medication therapy management, or actual or suspected medication-related problem
Exclusion criteria
* Not willing to participate in the study and sign informed consent; or * Non-English speaking or designated surrogate as translator not available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Qualitative description of process-related challenges and successes as assessed by observation and survey | 3 months | Implementation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quantitative description of bidirectional communication as assessed by turn-around times from pharmacist's recommendations delivered to prescriber's responses received | 3 months | Communication |
| Qualitative description of incorporation of pharmacogenomic testing into workflow and receptiveness as assessed by observation and survey | 3 months | Pharmacogenomic testing |
| Qualitative description of prescriber satisfaction with enhanced medication therapy management services as assessed by survey | 3 months | Prescriber survey |
| Qualitative and quantitative description of potential impact of enhanced medication therapy management services on drug regimens as assessed by before-and-after observations | 3 months | Impact |
Countries
United States
Outcome results
None listed